(Q34544811)

2 August 2017

Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers (English)

1 reference

2 August 2017

1 reference

Suresh Mallikaarjun

1

1 reference

PubMed ID

14747427

2 August 2017

Daniel E Salazar

series ordinal

2

1 reference

PubMed ID

14747427

2 August 2017

Steven L Bramer

series ordinal

3

1 reference

2 August 2017

1 February 2004

1 reference

The Journal of Clinical Pharmacology

2 August 2017

1 reference

2 August 2017

44

1 reference

2 August 2017

179-187

1 reference

2 August 2017

2

1 reference

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

2 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

Partial dopamine agonists in the treatment of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

Cardiovascular adverse effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

Neuroleptic-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

Prolactin levels and adverse events in patients treated with risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

Dose-dependent olanzapine-associated leukopenia: three case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003261901

21 January 2018

Identifiers

DOI

10.1177/0091270003261901

1 reference

2 August 2017

1 reference

PubMed ID

14747427